Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetic/PK data for ...
Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to develop and commercialize mosliciguat. Bayer received an upfront ...
Roivant Sciences (ROIV) traded sharply higher after its subsidiary Immunovant (IMVT) posted initial results from a Phase 2 trial evaluating its lead asset IMVT-1402 in rheumatoid arthritis, an ...
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and ...
BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid ...
Stocktwits on MSN
ROIV stock nears record high: Moderna settlement drives Q4 profit, but pipeline catalysts keep retail interested
Roivant posted a net income of $355.7 million or $0.28 per share, compared to consensus estimates of a loss of $0.34, according to Fiscal.ai data. ・The bottom line was lifted by a $770.2 million gain ...
Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...
Roivant financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to ...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (“Roivant”) today announced that the members of the Board of Directors of Arbutus Biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results